Litigation Details for Galderma Laboratories L.P. v. Lupin Inc. (D. Del. 2021)
✉ Email this page to a colleague
Galderma Laboratories L.P. v. Lupin Inc. (D. Del. 2021)
| Docket | ⤷ Sign Up | Date Filed | 2021-12-02 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | |
| Jury Demand | Defendant | Referred To | |
| Patents | 8,206,740 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Galderma Laboratories L.P. v. Lupin Inc.
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for Galderma Laboratories L.P. v. Lupin Inc. (D. Del. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2023-04-07 | 108 | Opinion - Memorandum Opinion | pharmaceutically acceptable excipients. U.S. Patent No. 8,206,740 cl. 1. Sun already construed the terms…company, Sun, for infringing the same patents. Many of the patents’ terms were construed in that suit. … slowly. Galderma patented its developments. Though Galderma has several patents and dozens of claims… “It is a bedrock principle of patent law that the claims of a patent define the in- vention to which…Galderma says Lupin infringes some of its drug patents. A few years ago, Gal- derma won a lawsuit against | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
